Oncothyreon to Present at Upcoming Investor Conferences


SEATTLE, Feb. 17, 2015 (GLOBE NEWSWIRE) -- Oncothyreon Inc. (Nasdaq:ONTY) announced today that Robert Kirkman, M.D., President and Chief Executive Officer, is scheduled to present at two upcoming investment conferences.

2015 RBC Capital Markets' Global Healthcare Conference

Tuesday, February 24, 2015 at 8 a.m. ET in New York.

Cowen and Company 35th Annual Healthcare Conference

Wednesday, March 4, 2015 at 8:40 a.m. ET in Boston.

A live and archived webcast of each presentation will be accessible by visiting the Oncothyreon website www.oncothyreon.com under the "News & Events" section.

About Oncothyreon

Oncothyreon is a clinical-stage biopharmaceutical company specializing in the development of innovative therapeutic products for the treatment of cancer. Our goal is to discover, develop and commercialize novel compounds that have the potential to improve the lives and outcomes of cancer patients. Our current clinical-stage product candidates include ONT-380, an orally active and selective small molecule HER2 inhibitor, and ONT-10, a therapeutic vaccine targeting MUC1. We are developing preclinical product candidates in oncology, and potentially certain rare diseases, using our protocell technology. For more information, visit www.oncothyreon.com.



            

Coordonnées